secwatch / observer
8-K filed September 20, 2023, 7:59 PM ET ticker IMDX CIK 0001642380
other confidence medium sentiment neutral materiality 0.30

Oncocyte subleases 13,400 sq ft of Irvine office to Induce Biologics

Insight Molecular Diagnostics Inc.

item 1.01item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Insight Molecular Diagnostics Inc. entered into Sublease Agreement with Induce Biologics USA, Inc. valued at Monthly base rent starting at $36,850.00, security deposit of $101,987.38 (effective 2023-09-14).

Action
entry
Agreement
lease
Counterparty
Induce Biologics USA, Inc.
Value
Monthly base rent starting at $36,850.00, security deposit of $101,987.38
Effective
2023-09-14
Exact text from the filing
On August 8, 2023, Oncocyte Corporation (the “ Company ”) and Induce Biologics USA, Inc. (“ Subtenant ”) entered into a Sublease Agreement (the “ Sublease Agreement ”), which subsequently became effective as of September 14, 2023, upon the execution and delivery by the Company, Subtenant, and Cushing Ventures, LLC (“ Landlord ”), of that certain Landlord’s Consent to Sublease dated September 12, 2023 (the “ Consent Agreement ”), under which Landlord consented to the Sublease Agreement, on the terms and subject to the conditions set forth therein.
View on SEC.gov

Browse all material agreements →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR
accession 0001493152-23-033143
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.